| Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML) (NCT01145846) | Cooperative Study Group A for Hematology | 2010-05-01 |
| Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission (NCT01096602) | Beth Israel Deaconess Medical Center | 2010-05-01 |
| ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies (NCT01110473) | AbbVie (prior sponsor, Abbott) | 2010-04-01 |
| A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML) (NCT01090167) | Genzyme, a Sanofi Company | 2010-02-01 |
| PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia (NCT01037556) | Proacta, Incorporated | 2010-01-01 |
| Ondansetron Versus Aprepitant Plus Ondansetron for Emesis (NCT00954941) | M.D. Anderson Cancer Center | 2009-11-01 |
| Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM) (NCT01146262) | Nantes University Hospital | 2009-11-01 |
| Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer (NCT00975975) | Indiana University | 2009-09-01 |
| Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine (NCT00995332) | University of Bergen | 2009-09-01 |
| Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes (NCT00981240) | Sanofi | 2009-09-01 |
| Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) (NCT00880269) | Novartis Pharmaceuticals | 2009-08-01 |
| A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML) (NCT00875693) | Weill Medical College of Cornell University | 2009-06-02 |
| MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia (NCT00911066) | Millennium Pharmaceuticals, Inc. | 2009-06-01 |
| Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes (NCT00923234) | Technische Universität Dresden | 2009-06-01 |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) (NCT00882102) | M.D. Anderson Cancer Center | 2009-04-01 |
| A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome (NCT00830518) | Millennium Pharmaceuticals, Inc. | 2009-02-10 |
| Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML) (NCT02662933) | Wake Forest University Health Sciences | 2009-01-01 |
| Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome (NCT00360672) | M.D. Anderson Cancer Center | 2009-01-01 |
| A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies (NCT00719836) | S*BIO | 2008-08-01 |
| Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (NCT02007863) | University of Miami | 2008-08-01 |
| Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) (NCT00720850) | Technische Universität Dresden | 2008-04-01 |
| A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS (NCT00656448) | M.D. Anderson Cancer Center | 2008-03-01 |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR (NCT01611298) | Robert Krance | 2008-03-01 |
| Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome (NCT00968071) | M.D. Anderson Cancer Center | 2008-02-01 |
| Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant (NCT00674427) | University of Pennsylvania | 2008-01-01 |
| Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) (NCT00686543) | Merck Sharp & Dohme LLC | 2007-12-01 |
| The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients (NCT00726934) | Indiana University | 2007-09-01 |
| A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) (NCT00510133) | Asterias Biotherapeutics, Inc. | 2007-07-01 |
| Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) (NCT00486265) | AstraZeneca | 2007-07-01 |
| Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD (NCT00539695) | Baylor College of Medicine | 2007-06-01 |
| Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) (NCT00579111) | Baylor College of Medicine | 2007-06-01 |
| Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL (NCT00529360) | New York Medical College | 2007-06-01 |
| Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation (NCT00374933) | Abramson Cancer Center at Penn Medicine | 2007-04-01 |
| Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia (NCT00623935) | University of Michigan Rogel Cancer Center | 2007-03-01 |
| Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML (NCT00430443) | Callisto Pharmaceuticals | 2007-02-01 |
| Effectiveness of Protected Environment Rooms for AML and MDS (NCT00443300) | M.D. Anderson Cancer Center | 2007-01-01 |
| Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) (NCT00412360) | Medical College of Wisconsin | 2006-12-01 |
| Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) (NCT00414310) | M.D. Anderson Cancer Center | 2006-12-01 |
| Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections (NCT00418951) | M.D. Anderson Cancer Center | 2006-11-01 |
| A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) (NCT00495287) | Northern Italy Leukemia Group | 2006-11-01 |
| A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) (NCT00373529) | Genzyme, a Sanofi Company | 2006-10-01 |
| A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) (NCT00317642) | Genzyme, a Sanofi Company | 2006-08-01 |
| Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) (NCT00398983) | M.D. Anderson Cancer Center | 2006-08-01 |
| Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia (NCT01289678) | Leo W. Jenkins Cancer Center | 2006-07-01 |
| An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia (NCT00346632) | Kyowa Kirin, Inc. | 2006-06-01 |
| AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia (NCT00321581) | National Cancer Institute (NCI) | 2006-05-01 |
| A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias. (NCT00315705) | Genzyme, a Sanofi Company | 2006-03-01 |
| Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) (NCT00285259) | Astellas Pharma Inc | 2006-01-31 |
| Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies (NCT00270881) | Keio University | 2006-01-01 |
| A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (NCT00324220) | Mirati Therapeutics Inc. | 2006-01-01 |
| Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) (NCT00569010) | M.D. Anderson Cancer Center | 2005-12-01 |
| Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting (NCT01031498) | M.D. Anderson Cancer Center | 2005-09-01 |
| Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS (NCT00334074) | Baylor Research Institute | 2005-08-01 |
| Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients (NCT00382590) | M.D. Anderson Cancer Center | 2005-08-01 |
| Phase II 5-Azacytidine Plus VPA Plus ATRA (NCT00326170) | M.D. Anderson Cancer Center | 2005-07-01 |
| Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome (NCT00760084) | Eisai Inc. | 2005-07-01 |
| MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia (NCT00274248) | Millennium Pharmaceuticals, Inc. | 2005-03-01 |
| Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML) (NCT00106600) | CTI BioPharma | 2005-03-01 |
| Unrelated Donor Stem Cell Transplantation (NCT01364363) | Scripps Health | 2005-03-01 |
| Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant (NCT00303667) | Masonic Cancer Center, University of Minnesota | 2005-01-01 |
| Differentiation Induction in Acute Myelogenous Leukemia (NCT00175812) | University of Bergen | 2004-11-01 |
| Low Dose Melphalan and Bortezomib for AML and High-Risk MDS (NCT00789256) | Dartmouth-Hitchcock Medical Center | 2004-09-01 |
| PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP (NCT00088231) | M.D. Anderson Cancer Center | 2004-07-01 |
| Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. (NCT00299780) | Massachusetts General Hospital | 2004-07-01 |
| Quality of Life of Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT00459524) | M.D. Anderson Cancer Center | 2004-04-01 |
| Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML (NCT00074737) | Eleos, Inc. | 2004-04-01 |
| Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor (NCT00304720) | Colorado Blood Cancer Institute | 2004-03-01 |
| Biology Studies of Hematologic Cancers (NCT00923442) | National Cancer Institute (NCI) | 2004-02-24 |
| Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML (NCT00382954) | University of Kentucky | 2004-02-01 |
| Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation (NCT00144677) | Dana-Farber Cancer Institute | 2003-11-01 |
| Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) (NCT00104468) | SGX Pharmaceuticals, Inc. | 2003-04-01 |
| Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT (NCT00516152) | University of California, San Francisco | 2002-11-01 |
| Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia (NCT01020539) | Columbia University | 2002-09-11 |
| Investigation of Clofarabine in Acute Leukemias (NCT00098033) | University of Texas | 2002-09-01 |
| Study of Gelonin Purging of Autologous Stem Cells for Transplantation (NCT00043810) | M.D. Anderson Cancer Center | 2002-07-01 |
| Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia (NCT00044889) | Genzyme, a Sanofi Company | 2002-05-01 |
| Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) (NCT00064584) | Millennium Pharmaceuticals, Inc. | 2002-05-01 |
| Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia (NCT00184054) | University of Southern California | 2002-04-01 |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies (NCT00683046) | University of Chicago | 2001-11-01 |
| Nonmyeloablative Allogeneic Transplant (NCT01272817) | Scripps Health | 2001-10-01 |
| High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML (NCT00474006) | Cooperative Study Group A for Hematology | 2001-08-01 |
| The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen (NCT01890486) | Wake Forest University Health Sciences | 2001-05-21 |
| Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS (NCT00038831) | M.D. Anderson Cancer Center | 2001-05-01 |
| Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia (NCT00116467) | Cell Genesys | 2001-03-01 |
| Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes (NCT00038870) | M.D. Anderson Cancer Center | 2001-01-31 |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant (NCT00571662) | University of Nebraska | 2000-12-08 |
| A Risk-Oriented Therapeutic Strategy for Adult Acute Myelogenous Leukemia (NCT00400673) | Northern Italy Leukemia Group | 2000-05-01 |
| Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant (NCT00044733) | Wyeth is now a wholly owned subsidiary of Pfizer | 2000-03-01 |
| Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia (NCT00136422) | Dana-Farber Cancer Institute | 2000-01-01 |
| Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow (NCT00003838) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-04-15 |
| A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (NCT00136461) | Dana-Farber Cancer Institute | 1997-05-01 |
| Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study) (NCT00015587) | National Institute of Environmental Health Sciences (NIEHS) | 1995-04-01 |
| High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML) (NCT00136448) | Dana-Farber Cancer Institute | 1993-02-01 |
| A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy (NCT00297921) | Millennium Pharmaceuticals, Inc. | |